Capstone Asset Management Co. lowered its stake in shares of Cambrex Corporation (NYSE:CBM) by 8.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,110 shares of the biotechnology company’s stock after selling 550 shares during the period. Capstone Asset Management Co.’s holdings in Cambrex Corporation were worth $365,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CBM. Beacon Financial Group increased its position in Cambrex Corporation by 15.5% in the second quarter. Beacon Financial Group now owns 6,526 shares of the biotechnology company’s stock valued at $391,000 after buying an additional 875 shares during the period. Clearbridge Investments LLC increased its position in Cambrex Corporation by 34.8% in the first quarter. Clearbridge Investments LLC now owns 971,174 shares of the biotechnology company’s stock valued at $53,463,000 after buying an additional 250,662 shares during the period. Public Employees Retirement System of Ohio increased its position in Cambrex Corporation by 40.5% in the first quarter. Public Employees Retirement System of Ohio now owns 136,464 shares of the biotechnology company’s stock valued at $7,512,000 after buying an additional 39,339 shares during the period. Bank of Nova Scotia increased its position in Cambrex Corporation by 9.5% in the first quarter. Bank of Nova Scotia now owns 10,492 shares of the biotechnology company’s stock valued at $577,000 after buying an additional 910 shares during the period. Finally, HighTower Advisors LLC bought a new position in Cambrex Corporation during the first quarter valued at about $438,000. Hedge funds and other institutional investors own 98.28% of the company’s stock.

Shares of Cambrex Corporation (NYSE:CBM) traded down 1.73% during midday trading on Wednesday, reaching $53.95. The company had a trading volume of 72,264 shares. The company’s 50 day moving average price is $59.25 and its 200 day moving average price is $55.49. The stock has a market capitalization of $1.76 billion, a PE ratio of 20.54 and a beta of 2.28. Cambrex Corporation has a 52-week low of $38.30 and a 52-week high of $62.95.

Cambrex Corporation (NYSE:CBM) last released its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, hitting the consensus estimate of $0.76. The company had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The firm’s revenue was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.68 earnings per share. Equities research analysts expect that Cambrex Corporation will post $3.08 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Cambrex Corporation (NYSE:CBM) Position Decreased by Capstone Asset Management Co.” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/09/cambrex-corporation-nysecbm-position-decreased-by-capstone-asset-management-co.html.

Several research firms have recently issued reports on CBM. BidaskClub upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Zacks Investment Research lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $64.00.

In other Cambrex Corporation news, Director Leon J. Hendrix, Jr. sold 20,656 shares of Cambrex Corporation stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the transaction, the director now owns 74,662 shares of the company’s stock, valued at $4,177,338.90. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total value of $736,680.00. Following the transaction, the chief executive officer now directly owns 95,328 shares in the company, valued at approximately $5,852,185.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 70,656 shares of company stock worth $4,064,423. 2.48% of the stock is currently owned by corporate insiders.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.